- Home
- KAVL vs BOLT Comparison
KAVL vs BOLT Comparison
Compare KAVL & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- BOLT
- Stock Information
- Founded
- KAVL 1998
- BOLT 2015
- Country
- KAVL United States
- BOLT United States
- Employees
- KAVL N/A
- BOLT N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- BOLT Health Care
- Exchange
- KAVL Nasdaq
- BOLT Nasdaq
- Market Cap
- KAVL 9.6M
- BOLT 9.4M
- IPO Year
- KAVL N/A
- BOLT 2021
- Fundamental
- Price
- KAVL $0.83
- BOLT $5.19
- Analyst Decision
- KAVL
- BOLT Buy
- Analyst Count
- KAVL 0
- BOLT 3
- Target Price
- KAVL N/A
- BOLT $47.50
- AVG Volume (30 Days)
- KAVL 463.0K
- BOLT 14.4K
- Earning Date
- KAVL 09-11-2025
- BOLT 08-14-2025
- Dividend Yield
- KAVL N/A
- BOLT N/A
- EPS Growth
- KAVL N/A
- BOLT N/A
- EPS
- KAVL N/A
- BOLT N/A
- Revenue
- KAVL $1,698,426.00
- BOLT $4,167,000.00
- Revenue This Year
- KAVL N/A
- BOLT N/A
- Revenue Next Year
- KAVL N/A
- BOLT N/A
- P/E Ratio
- KAVL N/A
- BOLT N/A
- Revenue Growth
- KAVL N/A
- BOLT N/A
- 52 Week Low
- KAVL $0.45
- BOLT $4.59
- 52 Week High
- KAVL $1.95
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- KAVL 53.04
- BOLT 46.64
- Support Level
- KAVL $0.78
- BOLT $4.81
- Resistance Level
- KAVL $1.16
- BOLT $5.28
- Average True Range (ATR)
- KAVL 0.14
- BOLT 0.26
- MACD
- KAVL -0.01
- BOLT 0.01
- Stochastic Oscillator
- KAVL 33.79
- BOLT 70.26
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.